Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

被引:312
作者
Kim, Michael P. [2 ,3 ]
Evans, Douglas B. [2 ]
Wang, Huamin [4 ]
Abbruzzese, James L. [5 ]
Fleming, Jason B. [2 ]
Gallick, Gary E. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
关键词
NUDE-MOUSE MODEL; IN-VIVO; DRUG DEVELOPMENT; HUMAN-CELLS; IDENTIFICATION; VITRO; LINE;
D O I
10.1038/nprot.2009.171
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
For decades, xenografts using well-established human tumor cell lines have been the most commonly used models to study human cancers in mice. More recently, human tumors implanted directly into immunodeficient mice have become increasingly popular as evidence accrues that they more accurately recapitulate features of patient tumors. Here we describe our protocols for the orthotopic and heterotopic implantation of pancreatic cancer cell lines and freshly isolated patient tumors into immunodeficient mice. We also describe procedures for the digestion of tumors into single-cell suspensions for the isolation of subpopulations of tumor cells. Orthotopic or heterotopic implantation of established cell lines requires 1-2 h, with 1-cm tumors arising after 2-5 weeks. Engraftment of patient tumor samples takes similar to 2 h and growth of palpable tumor requires similar to 14 weeks. Once established, direct xenograft tumors require 2 and 5 h for heterotopic and orthotopic implantation, respectively, and 5-6 weeks for palpable tumor growth.
引用
收藏
页码:1670 / 1680
页数:11
相关论文
共 31 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   A SEVERE COMBINED IMMUNODEFICIENCY MUTATION IN THE MOUSE [J].
BOSMA, GC ;
CUSTER, RP ;
BOSMA, MJ .
NATURE, 1983, 301 (5900) :527-530
[3]  
Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005
[4]  
End DW, 2001, CANCER RES, V61, P131
[5]   Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers [J].
Fichtner, Iduna ;
Rolff, Jana ;
Soong, Richie ;
Hoffmann, Jens ;
Hammer, Stefanie ;
Sommer, Anette ;
Becker, Michael ;
Merk, Johannes .
CLINICAL CANCER RESEARCH, 2008, 14 (20) :6456-6468
[6]   NUDE A NEW HAIRLESS GENE WITH PLEIOTROPIC EFFECTS IN MOUSE [J].
FLANAGAN, SP .
GENETICAL RESEARCH, 1966, 8 (03) :295-&
[7]   Maximizing mouse cancer models [J].
Frese, Kristopher K. ;
Tuveson, David A. .
NATURE REVIEWS CANCER, 2007, 7 (09) :645-658
[8]   A METASTATIC NUDE-MOUSE MODEL OF HUMAN PANCREATIC-CANCER CONSTRUCTED ORTHOTOPICALLY WITH HISTOLOGICALLY INTACT PATIENT SPECIMENS [J].
FU, XY ;
GUADAGNI, F ;
HOFFMAN, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (12) :5645-5649
[10]   Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors [J].
Gray, MJ ;
Wey, JS ;
Belcheva, A ;
McCarty, MF ;
Trevino, JG ;
Evans, DB ;
Ellis, LM ;
Gallick, GE .
CANCER RESEARCH, 2005, 65 (09) :3664-3670